Sandip Mitra

Dr. Sandip Mitra


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Health Technology Assessment
Verified
Journal Article
Closed access
PDF file
Sharlene A GreenwoodSharlene A Greenwood
Sharlene A Greenwood
PKPelagia Koufaki
Pelagia Koufaki
JMJamie Hugo Macdonald
Jamie Hugo Macdonald
CBCathy Bulley
Cathy Bulley
SBSunil Bhandari
Sunil Bhandari
TMThomas H Mercer
Thomas H Mercer
Background: Whether or not clinically implementable exercise interventions in haemodialysis patients improve quality of life remains unknown. Objectives: The PEDAL (PrEscription of intraDialytic exercise to improve quAlity of Life in patients with chronic kidney disease) trial evaluated the clinical effectiveness and cost-effectiveness of a 6-month intradialytic exercise programme on quality of life compared with usual care for haemodialysis patients. Design: We conducted a prospective, multicentre randomised controlled trial of haemodialysis patients from five haemodialysis centres in the UK and randomly assigned them (1 : 1) using a web-based system to (1) intradialytic exercise training plus usual-care maintenance haemodialysis or (2) usual-care maintenance haemodialysis. Setting: The setting was five dialysis units across the UK from 2015 to 2019. Participants: The participants were adult patients with end-stage kidney disease who had been receiving haemodialysis therapy for > 1 year. Interventions: Participants were randomised to receive usual-care maintenance haemodialysis or usual-care maintenance haemodialysis plus intradialytic exercise training. Main outcome measures: The primary outcome of the study was change in Kidney Disease Quality of Life Short Form, version 1.3, physical component summary score (from baseline to 6 months). Cost-effectiveness was determined using health economic analysis and the EuroQol-5 Dimensions, five-level version. Additional secondary outcomes included quality of life (Kidney Disease Quality of Life Short Form, version 1.3, generic multi-item and burden of kidney disease scales), functional capacity (sit-to-stand 60 and 10-metre Timed Up and Go tests), physiological measures (peak oxygen uptake and arterial stiffness), habitual physical activity levels (measured by the International Physical Activity Questionnaire and Duke Activity Status Index), fear of falling (measured by the Tinetti Falls Efficacy Scale), anthropometric measures (body mass index and waist circumference), clinical measures (including medication use, resting blood pressure, routine biochemistry, hospitalisations) and harms associated with intervention. A nested qualitative study was conducted. Results: We randomised 379 participants; 335 patients completed baseline assessments and 243 patients (intervention, n = 127; control, n = 116) completed 6-month assessments. The mean difference in change in physical component summary score from baseline to 6 months between the intervention group and control group was 2.4 arbitrary units (95% confidence interval –0.1 to 4.8 arbitrary units; p = 0.055). Participants in the intervention group had poor compliance (49%) and very poor adherence (18%) to the exercise prescription. The cost of delivering the intervention ranged from £463 to £848 per participant per year. The number of participants with harms was similar in the intervention (n = 69) and control (n = 56) groups. Limitations: Participants could not be blinded to the intervention; however, outcome assessors were blinded to group allocation. Conclusions: On trial completion the primary outcome (Kidney Disease Quality of Life Short Form, version 1.3, physical component summary score) was not statistically improved compared with usual care. The findings suggest that implementation of an intradialytic cycling programme is not an effective intervention to enhance health-related quality of life, as delivered to this cohort of deconditioned patients receiving haemodialysis. Future work: The benefits of longer interventions, including progressive resistance training, should be confirmed even if extradialytic delivery is required. Future studies also need to evaluate whether or not there are subgroups of patients who may benefit from this type of intervention, and whether or not there is scope to optimise the exercise intervention to improve compliance and clinical effectiveness. Trial registration: Current Controlled Trials ISRCTN83508514. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 40. See the NIHR Journals Library website for further project information.

30 May 2023 in Kidney International
Verified
Journal Article
Open access
SDSimon J. Davies
Simon J. Davies
DCDavid Coyle
David Coyle
ELElizabeth J. Lindley
Elizabeth J. Lindley
DKDavid Keane
David Keane
JBJohn Belcher
John Belcher
JSJulius Sim
Julius Sim
Avoiding excessive dialysis-associated volume depletion may help preserve residual kidney function (RKF). To establish whether knowledge of the estimated normally hydrated weight from bioimpedance measurements (BI-NHW) when setting the post-hemodialysis target weight (TW) might mitigate rate of loss of RKF, we undertook an open label, randomized controlled trial in incident patients receiving HD, with clinicians and patients blinded to bioimpedance readings in controls. A total of 439 patients with over 500 ml urine/day or residual GFR exceeding 3 ml/min/1.73m2 were recruited from 34 United Kingdom centers and randomized 1:1, stratified by center. Fluid assessments were made for up to 24 months using a standardized proforma in both groups, supplemented by availability of BI-NHW in the intervention group. Primary outcome was time to anuria, analyzed using competing-risk survival models adjusted for baseline characteristics, by intention to treat. Secondary outcomes included rate of RKF decline (mean urea and creatinine clearance), blood pressure and patient-reported outcomes. There were no group differences in cause-specific hazard rates of anuria (0.751; 95% confidence interval (0.459, 1.229)) or sub-distribution hazard rates (0.742 (0.453, 1.215)). RKF decline was markedly slower than anticipated, pooled linear rates in year 1: -0.178 (-0.196, -0.159)), year 2: -0.061 (-0.086, -0.036)) ml/min/1.73m2/month. Blood pressure and patient reported outcomes did not differ by group. The mean difference agreement between TW and BI-NHW was similar for both groups, Bioimpedance: -0.04 kg; Control: -0.25 kg. Thus, use of a standardized clinical protocol for fluid assessment when setting TW is associated with excellent preservation of RKF. Hence, bioimpedance measurements are not necessary to achieve this.

30 June 2023 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
RSRukshana Shroff
Rukshana Shroff
CBCarlo Basile
Carlo Basile
FSFrank van der Sande
Frank van der Sande
SMSandip Mitra
Sandip Mitra
TAthe EuDial Working Group of the European Renal Association
the EuDial Working Group of the European Renal Association
BMBjörn Meijers
Björn Meijers
Rukshana Shroff, Carlo Basile, Frank van der Sande, Sandip Mitra, EuDial Working Group* of the European Renal Association , Christian Combe, Gaetano Alfano, Adr

Verified
Journal Article
Open access
PDF file
NMNicos Mitsides
Nicos Mitsides
VMVikram Mitra
Vikram Mitra
ASAnanya Saha
Ananya Saha
SHShelley Harris
Shelley Harris
PKPhilip A. Kalra
Philip A. Kalra
SMSandip Mitra
Sandip Mitra
Chronic kidney disease (CKD) is a major public health concern with an increasing proportion of sufferers progressing to renal replacement therapy (RRT). Early identification of those at risk of disease progression could be key in improving outcomes. We hypothesise that urinary liver-type fatty acid binding protein (uL-FABP) may be a suitable biomarker for CKD progression and can add value to currently established biomarkers such as the urinary protein-to-creatinine ratio (uPCR). A total of 583 participants with CKD 1–5 (not receiving renal replacement therapy) entered a 2 yr prospective longitudinal study. UPCR and uL-FABP were measured at baseline and CKD progression was defined as either (i) a decline in eGFR of >5 mL/min/1.73 m2 or an increase in serum creatinine by 10% at 1 yr; (ii) a decline in eGFR of >6 mL/min/1.73 m2 or an increase in serum creatinine by 20% at 2 yrs; or (iii) the initiation of RRT. A combined outcome of initiating RRT or death was also included. Approximately 40% of participants showed CKD progression. uL-FABP predicted CKD progression at both years 1 and 2 (OR 1.01, p < 0.01). Sensitivity and specificity were comparable to those of uPCR (AUC 0.623 v 0.706) and heat map analysis suggested that uL-FABP in the absence of significant proteinuria can predict an increase in serum creatinine of 10% at 1 yr and 20% at 2 yrs. The risk of the combined outcome of initiating RRT or death was 23% higher in those with high uL-FABP (p < 0.01) independent of uPCR. uL-FABP appears to be a highly sensitive and specific biomarker of CKD progression. The use of this biomarker could enhance the risk stratification of CKD and its progression and should be assessed further.

18 March 2018 in The Journal of Vascular Access
Verified
Journal Article
Closed access
VJVictoria E Jackson
Victoria E Jackson
HHHelen Hurst
Helen Hurst
SMSandip Mitra
Sandip Mitra
Introduction: Arteriovenous fistulae remain the gold standard of vascular access in haemodialysis. There is currently no consensus on standardised methods of monitoring arteriovenous fistulae. Assessment techniques and practice remain widely variable. The purpose of this study is to determine whether existing evidence supports physical assessment as an effective tool and a good predictor of arteriovenous fistulae dysfunction to allow for timely intervention and improve outcomes. Methods: A literature search was performed using CINAHL, PubMed, Medline and BNI databases and relevant search terms. Studies included were peer-reviewed, published after 2008, in English and related to arteriovenous fistulae only. Six key papers were identified and critically analysed for validity and relevance, in relation to outcomes, assessor experience, training duration and nurses’ ability to perform physical assessment. Results: Physical assessment has been shown to be effective in detecting arteriovenous fistulae dysfunction and comparable to technology-based surveillance. Physical assessment techniques generally adopt a ‘look, listen and feel’ approach to identify arteriovenous fistulae dysfunction that includes stenosis, thrombosis, ischaemia and infections. Physical assessment is a skill that can be taught with studies showing that skill-specific training is more effective than experience alone. Cost-effectiveness analysis is lacking. Conclusion: The analysis of evidence demonstrates that physical assessment of arteriovenous fistulae is an effective method of detecting arteriovenous fistulae dysfunction and is a skill that can be taught. A structured physical assessment and its implementation may be significant in routine care, but research into the most effective physical assessment techniques and its impact on clinical practice in haemodialysis is required.

10 October 2024 in Kidney360
Verified
Journal Article
Open access
JBJohn Belcher
John Belcher
DCDavid Coyle
David Coyle
ELElizabeth J. Lindley
Elizabeth J. Lindley
DKDavid Keane
David Keane
FCFergus J. Caskey
Fergus J. Caskey
SDSimon J. Davies
Simon J. Davies
Key Points: Residual kidney function during the first 2 years of hemodialysis treatment is associated with a long-term (>4 years) survival advantage. Incorporating bioimpedance measurements to inform the setting of the postdialysis target weight does not affect patient survival. Background: Preservation of residual kidney function (RKF) in dialysis patients has been associated with improved survival. RKF in the BISTRO trial was relatively well preserved, and in this study, we describe its association with survival during the trial and extended follow-up. Methods: RKF, measured as the average urea and creatinine clearance (GFR) or 24-hour urine volume, was assessed at baseline; 1, 2, and 3 months; and every three months for up to 2 years in incident hemodialysis patients. Time to event survival data or competing events (transplantation, modality change) was obtained for 50 months after enrollment via data linkage with the UK Renal Registry. Cox proportional hazards regression survival models, including those incorporating change in GFR from baseline as a time-varying variable and joint regression models for longitudinal and survival data (longitudinal models for GFR or urine volume), were used to explore the relationship of RKF preservation with survival. Analyses were adjusted for age, sex, comorbidity, and ethnicity. Results: A total of 2919 measures of RKF were made in 387 patients from 32 UK dialysis units. Higher age and comorbidity score were associated with increased mortality in all models. Baseline GFR reduced the risk of death (hazard ratio [HR], 0.918; 95% confidence interval [CI], 0.844 to 0.999) per ml/min per 1.73 m2. A greater fall in GFR and urine volume from baseline was associated with a nonsignificant increased risk of death, as visualized on spline plots. In the joint survival models, higher GFR (adjusted HR, 0.88; 95% CI, 0.80 to 0.97) or urine volume (adjusted HR, 0.75, 95% CI, 0.57 to 0.95/L) at any time point was associated with better survival. Conclusions: Lower RKF during the first 2 years of hemodialysis is associated with an increased death risk for up to 50 months after dialysis initiation. This adds to a growing body of evidence that interventions to preserve RKF should be developed and tested in clinical trials.